Review Article
Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience
Table 4
Table showing the studies using metronomic regimens in hepatocellular cancer. UFT, Tegafur-5 FU.
| Author | Treatment | N | Patient type | SD | PR | CR | ORR | TTP | PFS | OS |
| Hsu, 2010 | Sorafenib 400 mg bid UFT 125mg/m2 | 53 | Untreated, Child-Pugh class A | 26 (49%) | 4 (8%) | | | | 3.7 m | 7.4 m |
| Boige, 2012 | Bevacizumab 5 mg/kg or 10 mg/kg q14d | 43 | Advanced | N/A | 6 (14.0%) | N/A | 14.0% | | | |
| Shao, 2012 | Thalidomide 100 mg bid UFT 125mg/m2 | 43 | Untreated, | | | | 9% | | 1.9 m | |
| Woo, 2012 | (Into the hepatic artery) Epirubicin 30 mg/m2 q28d Cisplatin 15mg/m2 q21d 5-FU 50 mg/m2 q21d | 30 | Portal vein thrombosis | | 6 (20.0%) | | | 63 d | | 63 d |
| Brandi, 2013 | Capecitabine 500 mg bid | 59 | Untreated | 30 | 1 | 2 | | | 6.03 m | 14.47 m | 31 | Sorafenib refractory | 10 | N/A | N/A | | | 3.27 m | 9.77 m |
| Granito, 2015 | Capecitabine 500 mg bid | 26 | Sorafenib refractory | | | | | 4 m | | 8 m |
|
|